登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Coagulation Factor III】

Coagulation Factor III信息

英文名称:Tissue factor
中文名称:组织因子
靶点别称:Coagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
上市药物数量:1
临床药物数量:4
最高研发阶段:批准上市

Coagulation Factor III产品列表

ACRO质量管理体系
 
评论(2)
TF3-H52H5|Human Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified)
  1. 151XXXXXXX0
  2. 0人赞
  3. 选择acro的产品,实验无忧无虑,从包装容器就可以看出,是一家很用心的一家公司。这个很好,没得话说。物流合作顺丰速度很快,包装容器很好看,很完美。还可以回收。物流速度超级快。TF蛋白已经多次购买,实验重复性很好。acro真的值得信赖,靠谱。ACRO非常不错.
  4. 2023-11-30
TF3-H52H5|Human Coagulation Factor III / Tissue Factor Protein, His Tag (active enzyme, MALS verified)
  1. 151XXXXXXX0
  2. 0人赞
  3. 本次购买的TF蛋白产品主要用于筛选抗体,应用于ELISA实验 ,结合实验也取得了满意的实验结果,曲线响应很好,上下平台都有!
  4. 2024-03-21
 

Coagulation Factor III 分子别名

Coagulation Factor III,Tissue Factor,TF,F3,CD142

Coagulation Factor III 分子背景

Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Coagulation Factor III 前沿进展

Coagulation Factor III上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Tisotumab vedotin TF-011-MMAE 批准上市 Genmab A/S HuMax-TF, TIVDAK United States 宫颈癌 Seagen Inc 2021-09-20 卵巢癌, 实体瘤, 食道癌, 头颈部鳞状细胞癌, 胰腺癌, 膀胱癌, 前列腺癌, 腹膜癌, 结直肠癌, 子宫内膜癌, 输卵管癌, 非小细胞肺癌, 宫颈癌 详情

Coagulation Factor III临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Recombinant NAPc2 AB-201 临床三期 Dendreon Uk Ltd 新型冠状病毒感染 详情
XB-002 ICON-2; XB-002 临床一期 Iconic Therapeutics Inc 实体瘤, 头颈部鳞状细胞癌, 胰腺癌, 卵巢上皮癌, 三阴性乳腺癌, 去势抵抗性前列腺肿瘤, 乳腺癌, 食管鳞状细胞癌, 子宫内膜癌, 泌尿生殖道肿瘤, 宫颈癌, 非小细胞肺癌 详情
XNW-28012 XNW-28012; XNW28012 临床二期 上海信诺维生物医药有限公司 实体瘤 详情
MRG004A MRG004A 临床二期 上海美雅珂生物技术有限责任公司 实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定